Reversal of quinpirole inhibition of ventral tegmental area neurons is linked to the phosphatidylinositol system and is induced by agonists linked to Gq

Journal of Neurophysiology

Volumn 108, Issue 1, 2012, Pages 263-274

  Nimitvilai, Sudarat ^a   McElvain, Maureen A ^a   Arora, Devinder S ^a   Brodie, Mark S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Desensitization; Dopamine D2 receptor; Neurotensin; Protein kinase C; Serotonin

Indexed keywords

ADENYLATE CYCLASE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; METABOTROPIC RECEPTOR; NEUROTENSIN RECEPTOR; PHOSPHATIDYLINOSITOL; QUINPIROLE; SEROTONIN 1B RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SKF83822; SKF83959; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; BRAIN SLICE; CONCENTRATION (PARAMETERS); DESENSITIZATION; DRUG INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; SECOND MESSENGER; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; KETANSERIN; NEUROTENSIN; PHENYLEPHRINE; PHOSPHATIDYLINOSITOLS; QUINPIROLE; RATS; RATS, INBRED F344; SEROTONIN; VENTRAL TEGMENTAL AREA;

EID: 84863323813     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.01137.2011     Document Type: Article

References (107)

1. Azmitia E, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179: 641-667, 1978.
2. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, Kharazia V, Waldhoer M, Mailliard WS, Armstrong R, Bonci A, Whistler JL. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 102: 11521-11526, 2005.
3. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem 275: 32672-32680, 2000.
4. Borgland S, Malenka R, Bonci A. Acute and chronic cocaine-induced potentiation of synaptic strength in the ventral tegmental area: electrophysiological and behavioral correlates in individual rats. J Neurosci 24: 7482-7490, 2004.
5. Bouthenet M, Souil E, Martres M, Sokoloff P, Giros B, Schwartz J. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203-219, 1991.
6. Brodie MS, Bunney EB. Serotonin potentiates dopamine inhibition of ventral tegmental area neurons in vitro. J Neurophysiol 76: 2077-2082, 1996.
7. Brodie MS, Dunwiddie TV. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro. Brain Res 425: 106-113, 1987.
8. Brodie MS, McElvain MA, Bunney EB, Appel SB. Pharmacological reduction of small conductance calcium-activated potassium current (SK) potentiates the excitatory effect of ethanol on ventral tegmental area dopamine neurons. J Pharmacol Exp Ther 290: 325-333, 1999.
9. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 508: 65-69, 1990.
10. Brodie MS, Trifunovic RD, Shefner SA. Serotonin potentiates ethanolinduced excitation of ventral tegmental area neurons in brain slices from three different rat strains. J Pharmacol Exp Ther 273: 1139-1146, 1995.
11. Bubar M, Cunningham K. Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146: 286-297, 2007.
12. Bunney BS, Walters JR, Roth RH, Aghajanian GK. Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560-571, 1973.
13. Caillé I, Dumartin B, Bloch B. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730: 17-31, 1996.
14. Chieng B, Azriel Y, Mohammadi S, Christie MJ. Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. J Physiol 589: 3775-3787, 2011.
15. Cho DI, Beom S, Van Tol HH, Caron MG, Kim KM. Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D4 receptors. Biochem Biophys Res Commun 350: 634-640, 2006.
16. 5receptor immunolocalization in rat and monkey brain. Synapse 37: 125-145, 2000.
17. Clemet D, Punhani T, Duxon M, Blackdurn T, Fone K. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39: 123-132, 2000.
18. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47, Suppl 1: 227-241, 2004.
19. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic dopamine system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278, 1988.
20. Diaz J, Levesque D, Lammers C, Griffon N, Martres M, Schwartz J, Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65: 731-745, 1995.
21. Doherty M, Pickel V. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864: 176-185, 2000.
22. Drouin C, Blanc G, Villégier A, Glowinski J, Tassin J. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse 43: 51-61, 2002a.
23. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin J. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22: 2873-2884, 2002b.
24. Felder C, Jose P, Axelord J. The dopamine-1 agonist SKF82526 stimulates phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther 248: 171-175, 1989.
25. Ferrè S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K. Adenosine A2A group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 38: 129-140, 1999.
26. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monoamine nerve terminals in the central nervous system. Acta Physiol Scand Suppl 247: 37γ, 1965.
27. Gao C, Wolf ME. Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J Neurochem 106: 2489-2501, 2008.
28. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4: 2866-2876, 1984.
29. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller H, Johannes F. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett 392: 77-80, 1996.
30. Guiard B, El Mansari M, Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 74: 1463-1475, 2008.
31. Gurevich E, Joyce J. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20: 60-80, 1999.
32. Hervé D, Pickel VM, Joh T, Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435: 71-83, 1987.
33. Ikemoto K, Nishimura A, Okado N, Mikuni M, Nishi K, Nagatsu I. Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration. Brain Res 853: 377-380, 2000.
34. Jennes L, Stumpf W, Kalivas P. Neurotensin: topographical distribution in rat brain by immunohistochemistry. J Comp Neurol 210: 211-224, 1982.
35. Jiang ZG, Pessia M, North RA. Neurotensin excitation of rat ventral tegmental neurones. J Physiol 474: 119-129, 1994.
36. Jiménez-Rivera C, Feliu-Mojer M, Vázquez-Torres R. Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann NY Acad Sci 1074: 390-402, 2006.
37. Jin L, Goswami S, Cai G, Zhen X, Friedman E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 85: 378-386, 2003.
38. Jomphe C, Lemelin P, Pkano H, Kobayashi K, Trudeau L. Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons. Eur J Neurosci 24: 2789-2800, 2006.
39. Kenakin TP. Analysis of dose-response data. In: Pharmacologic Analysis of Drug-Receptor Interaction. New York: Raven, 1987, p. 129-162.
40. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la Calle A. Dopamine D5 receptors of rat and human brain. Neuroscience 100: 689-699, 2000.
41. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95: 7731-7736, 1998.
42. Kilpatrick GJ, Hagan RM, Gale JD. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav Brain Res 73: 11-13, 1996.
43. Lacey M. Neurotransmitter receptors, and ionic conductances regulating the activity of neurones in substantia nigra pars compacta and ventral tegmental area. Prog Brain Res 99: 251-276, 1993.
44. Lacey MG, Mercuri NB, North RA. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol 392: 397-416, 1987.
45. Lacey MG, Mercuri NB, North RA. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. J Neurosci 9: 1233-1241, 1989.
46. Lammel S, Hetzel A, Hackel O, Jones I, Liss B, Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57: 760-773, 2008.
47. Lee S, So C, Rashid A, Varghese G, Cheng R, Lanca A, O'Dowd B, George S. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279: 35671-35678, 2004.
48. Li X, Ferraro L, Tanganelli S, O'Connor W, Hasselrot U, Ungerstedt U, Fuxe K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J Neural Transm Gen Sect 102: 125-137, 1995.
49. Liu YF, Civelli O, Grandy DK, Albert PR. Differential sensitivity of the short and long human dopamine D2 receptor subtypes to protein kinase C. J Neurochem 59: 2311-2317, 1992.
50. h) in ventral tegmental area dopamine neurons: involvement of 5-HT2 receptors and protein kinase C. J Neurophysiol 90: 3201-3212, 2003.
51. Luu P, Malenka R. Spike timing-dependent long-term potentiation in ventral tegmental area dopamine cells requires PKC. J Neurophysiol 100: 533-538, 2008.
52. Margolis EB, Lock H, Hjelmstad GO, Fields HL. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? J Physiol 577: 907-924, 2006.
53. 2receptor inhibition. J Neurosci 28: 8908-8913, 2008.
54. Martin L, Blackstone C, Huganir R, Price D. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9: 259-270, 1992.
55. Martiny-Boron G, Kazanietz M, Mischak H, Blumberg P, Kochs G, Hug H, Marme D, Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem 268: 9194-9197, 1993.
56. Meador-Woodruff JH, Mansour A, Grandy DK, Damask SP, Civelli O, Watson SJ Jr. Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 145: 209-212, 1992.
57. Mengod G, Nguyen H, Le H, Waeber C, Lubbert H, Palacios J. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35: 577-591, 1990a.
58. Mengod G, Pompeiano M, Martinez-Mir M, Palacios J. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res 524: 139-143, 1990b.
59. Mengod G, Villaro M, Landwehrmever G, Martinez-Mir M, Niznik H, Sunahara R, Seeman P, O'Dowd B, Probst A, Palacios J. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 20: 33S-43S, 1992.
60. Mercuri N, Stratta F, Calabresi P, Bonci A, Bernadi G. Activation of metabotropic glutamate receptors induces an inward current in rat dopamine mesencephalic neurons. Neuroscience 56: 399-407, 1993.
61. Mirenowicz J, Schultz W. Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Nature 379: 449-451, 1996.
62. Missale C, Nash S, Robinson S, Jaber M, Caron M. Dopamine receptors: from structure to function. Physiol Rev 78: 189-225, 1998.
63. Morilak D, Garlow S, Ciaranello R. Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience 54: 701-717, 1993.
64. Morris SJ, Van-Ham II, Daigle M, Robillard L, Sajedi N, Albert PR. Differential desensitization of dopamine D2 receptor isoforms by protein kinase C: the importance of receptor phosphorylation and pseudosubstrate sites. Eur J Pharmacol 577: 44-53, 2007.
65. Mueller AL, Brodie MS. Intracellular recording from putative dopaminecontaining neurons in the ventral tegmental area of Tsai in a brain slice preparation. J Neurosci Methods 28: 15-22, 1989.
66. Murphy M. Dopamine: a role in the pathogenesis, and treatment of hypertension. J Hum Hypertens 14: S47-S50, 2000.
67. Namkung Y, Sibley DR. Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J Biol Chem 279: 49533-49541, 2004.
68. Neve K, Seamans J, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205, 2004.
69. Nimitvilai S, Arora D, Brodie M. Reversal of dopamine inhibition of dopaminergic neurons of the ventral tegmental area is mediated by protein kinase C. Neuropsychopharmacology 37: 543-556, 2012.
70. Nimitvilai S, Brodie MS. Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area. J Pharmacol Exp Ther 333: 555-563, 2010.
71. Olijslagers J, Werkman T, McCreary A, Kruse C, Wadman W. Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action. Curr Neuropharmacol 4: 59-68, 2006.
72. O'Sullivan G, Roth B, Kinsella A, Waddinton J. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. Eur J Pharmacol 486: 273-280, 2004.
73. Palacios J, Kuhar M. Neurotensin receptors are located on dopaminecontaining neurones in rat midbrain. Nature 294: 587-589, 1981.
74. 35S]GTPγS binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropsychopharmacology 40: 826-837, 2001.
75. Pesavento E, Margotti E, Righi M, Cattaneo A, Domenici L. Blocking the NGFTrkA interaction rescues the developmental loss of LTP in the rat visual cortex: role of the cholinergic system. Neuron 25: 165-175, 2000.
76. Pierce R, Born B, Adams M, Kalivas P. Repeated intra-ventral tegmental area administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge. J Pharmacol Exp Ther 278: 384-392, 1996.
77. Popoli P, Pèzzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, Fuxe K, Ferrè S. The selective mGlu5 receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D2 receptors in the rat striatum interactions with adenosine A2a receptors. Neuropsychopharmacology 25: 505-513, 2001.
78. Quirion R, Chiueh C, Everist H, Pert A. Comparative localization of neurotensin receptors on nigrosriatal and mesolimbic dopaminergic terminals. Brain Res 327: 385-389, 1985.
79. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF, George SR. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104: 654-659.
80. Riberio F, Paquet M, Cregan S, Ferguson S. Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets 9: 574-595, 2010.
81. 4receptors in the rat cerebral cortex and their relationship with the cortical dopaminergic and noradrenergic nerve terminal networks. Neuroscience 155: 997-1010, 2008.
82. Rogue P, Zwiller J, Malviya A, Vincendon G. Phosphorylation by protein kinase C modulates agonist binding to striatal dopamine D2 receptors. Biochem Int 22: 575-582, 1990.
83. Seutin V, Massotte L, Dresse A. Electrophysiological effects of neurotensin on dopaminergic neurones of the ventral tegmental area of the rat in vitro. Neuropharmacology 28: 949-954, 1989.
84. Shi W, Bunney B. Neurotensin attenuates dopamine D2 agonist quinpiroleinduced inhibition of midbrain dopamine neurons. Neuropharmacology 29: 1095-1097, 1990.
85. Sibley D, Monsma FJ, Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 35: 391-415, 1993.
86. Skeberdis V, Lan J, Opitz T, Zheng X, Bennett M, Zukin R. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 40: 856-865, 2001.
87. So CH, Varghese G, Curley KJ, Kong MM, Alijanjaram M, Ji X, Nguyen T, O'Dowd BF, George SR. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 68: 568-578, 2005.
88. Sokolov M, Kleschevnikov A. Atropine suppresses associative LTP in the CA1 region of rat hippocampal slices. Brain Res 672: 281-284, 1995.
89. St-Gelais F, Legault M, Bourgue M, Rompré PT. Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci 24: 2566-2574, 2004.
90. Steinbusch H. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6: 557-618, 1981.
91. Steketee J. Injection of SCH 23390 into the ventral tegmental area blocks the development of neurochemical but not behavioral sensitization to cocaine. Behav Pharmacol 9: 69-76, 1998.
92. Stoof J, Kebabian J. Opposing roles for D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366-368, 1981.
93. Stowe Z, Bissette G, Nemeroff C. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs. Yakubutsu Seishin Kodo 11: 49-59, 1991.
94. Sun X, Milovanovic M, Zhao Y, Wolf ME. Acute and chronic dopamine receptor stimulation modulates AMPA receptor trafficking in nucleus accumbens neurons cocultured with prefrontal cortex neurons. J Neurosci 28: 4216-4230, 2008.
95. Testa C, Standaert D, Young A, Penney JJ. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14: 3005-3018, 1994.
96. Thibault D, Albert P, Pineyro G, Trudeau L. Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism. J Biol Chem 286: 9174-9184, 2011.
97. Tobler P, Fiorillo CD, Schultz W. Adaptive coding of reward value by dopamine neurons. Science 307: 1642-1645, 2005.
98. Uhl G. Distribution of neurotensin, and its receptor in the central nervous system. Ann NY Acad Sci 400: 132-149, 1982.
99. Uhl G, Kuhar M, Snyder S. Neurotensin: immunohistochemical localization in rat central nervous system. Proc Natl Acad Sci USA 74: 4059-4063, 1977.
100. Undie A, Weinstock J, Sarau H, Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62: 2045-2048, 1994.
101. Ungless M, Whistler J, Malenka R, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411: 583-587, 2001.
102. Van Bockstaele E, Cestari D, Pickel V. Synaptic structure and connectivity of serotonin area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res 647: 307-322, 1994.
103. von Euler G, van der Ploeg I, Fredholm B, Fuxe K. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. J Neurochem 56: 178-183, 1991.
104. Werkman T, Kruse C, Nievelstein H, Long S, Wadman W. Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Neuroscience 95: 417-423, 2000.
105. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 6: 243-251, 1996.
106. Wu T, Li A, Wang HL. Neurotensin increases the cationic conductance of rat substantia nigra dopaminergic neurons through the inositol 1,4,5-trisphosphate-calcium pathway. Brain Res 683: 242-250, 1995.
107. 2+. Hippocampus 10: 57-63, 2000.